Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$984M |
| 2 |
State Street Utilities Select Sector SPDR ETF
XLU
|
+$406M |
| 3 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$363M |
| 4 |
Comcast
CMCSA
|
+$305M |
| 5 |
DuPont de Nemours
DD
|
+$229M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.98B |
| 2 |
Linde
LIN
|
+$1.14B |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$976M |
| 4 |
AGN
Allergan plc
AGN
|
+$735M |
| 5 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$469M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 9.7% |
| 2 | Financials | 4.92% |
| 3 | Consumer Discretionary | 4.46% |
| 4 | Healthcare | 4.33% |
| 5 | Communication Services | 4.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4126
CALL
Neurocrine Biosciences
NBIX
$16.2B
| $171K | ﹤0.01% |
1,400
-20,200
| -94% | -$2.23M |
|
4127
Invesco CurrencyShares Canadian Dollar Trust
FXC
$69.7M
| $170K | ﹤0.01% |
2,346
-3,559
| -60% | -$253K |
|
|
JCAP
4128
DELISTED
Jernigan Capital, Inc.
JCAP
| $170K | ﹤0.01% |
12,442
+5,067
| +69% | +$65.2K |
|
4129
CALL
Hershey
HSY
$36.8B
| $169K | ﹤0.01% |
1,300
-10,700
| -89% | -$1.44M |
|
|
KALV
4130
DELISTED
KalVista Pharmaceuticals
KALV
| $169K | ﹤0.01% |
14,001
+3,322
| +31% | +$35.3K |
|
4131
iShares Broad USD Investment Grade Corporate Bond ETF
USIG
$17.3B
| $169K | ﹤0.01% |
2,800
-185,071
| -99% | -$10.8M |
|
|
HEP
4132
DELISTED
Holly Energy Partners, L.P.
HEP
| $169K | ﹤0.01% |
11,568
+4,412
| +62% | +$64.7K |
|
4133
UNIFI
UFI
$128M
| $168K | ﹤0.01% |
13,016
+987
| +8% | +$11.7K |
|
4134
Vishay Precision Group
VPG
$905M
| $168K | ﹤0.01% |
6,824
+3,363
| +97% | +$75.6K |
|
4135
Verastem
VSTM
$519M
| $168K | ﹤0.01% |
+8,180
| New | +$216K |
|
|
BCOV
4136
DELISTED
Brightcove, Inc.
BCOV
| $168K | ﹤0.01% |
21,468
+8,512
| +66% | +$68.5K |
|
4137
CALL
American Electric Power
AEP
$68.2B
| $167K | ﹤0.01% |
2,100
-43,400
| -95% | -$3.54M |
|
4138
First Bank
FRBA
$458M
| $167K | ﹤0.01% |
25,630
+20,090
| +363% | +$142K |
|
4139
Tejon Ranch
TRC
$444M
| $167K | ﹤0.01% |
11,551
+4,618
| +67% | +$64.3K |
|
4140
Utah Medical Products
UTMD
$223M
| $167K | ﹤0.01% |
+1,887
| New | +$169K |
|
|
AMRS
4141
DELISTED
Amyris Inc.
AMRS
| $167K | ﹤0.01% |
39,027
+19,201
| +97% | +$63.8K |
|
|
GRAF.U
4142
DELISTED
Graf Industrial Corp. Units, each consisting of One share of Common Stock and One redeemable Warrant
GRAF.U
| $166K | ﹤0.01% |
10,000
-140,000
| -93% | -$1.64M |
|
4143
Citizens
CIA
$231M
| $165K | ﹤0.01% |
27,331
+10,882
| +66% | +$62.5K |
|
4144
CRA International
CRAI
$1.14B
| $165K | ﹤0.01% |
4,164
+1,055
| +34% | +$40.1K |
|
4145
Paysign
PAYS
$693M
| $165K | ﹤0.01% |
17,050
-7,348
| -30% | -$54.2K |
|
4146
PUT
Prospect Capital
PSEC
$1.11B
| $165K | ﹤0.01% |
32,200
-6,500
| -17% | -$30.4K |
|
4147
UFP Technologies
UFPT
$2.41B
| $165K | ﹤0.01% |
3,759
+1,503
| +67% | +$64.3K |
|
|
TLRD
4148
PUT
DELISTED
Tailored Brands, Inc.
TLRD
| $165K | ﹤0.01% |
175,500
+27,000
| +18% | +$35.7K |
|
|
BCLI
4149
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $164K | ﹤0.01% |
+978
| New | +$105K |
|
4150
Dianthus Therapeutics
DNTH
$6.15B
| $164K | ﹤0.01% |
1,363
+823
| +152% | +$116K |
|
Similar funds
Barclays's Q2 2020 Portfolio in Review
As of Q2 2020, Barclays held 6,627 positions worth $129B, up 2.3% from $127B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Barclays withdrew a net $22.7B in Q2 2020, closing 960 positions and reducing 2,655 holdings. Its most notable exit was Allergan plc, an estimated $735M position sold in full.
By sector, the portfolio is most concentrated in Technology at 9.7% of assets, up from 8.3% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in iShares MSCI ACWI ex US ETF worth $123M.
- Barclays's largest Q2 2020 buy was iShares MSCI ACWI ex US ETF: 2,853,067 shares worth $123M.
- Barclays added most to iShares iBoxx $ High Yield Corporate Bond ETF in Q2 2020, an estimated $984M increase.
- Barclays's biggest Q2 2020 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.98B.
- Barclays fully exited Allergan plc in Q2 2020, selling an estimated $735M.
- Barclays's ten largest holdings make up 34% of its $129B portfolio in Q2 2020.
- Barclays opened 468 new positions and closed 960 in Q2 2020.
- Barclays's portfolio value rose 2.3% quarter-over-quarter to $129B.
Based on Barclays's 13F filing for Q2 2020, filed 12 Aug 2020.